Reports
Sale
Nasopharyngeal Cancer Market Size, Share, Trends, Growth: By Therapy: Chemotherapy, Immunotherapy, Radiation therapy, Others; By Diagnosis: Biopsy, MRI, Others; By Stages: Stage 1, Stage 2, Stage 3, Stage 4; By End User: Hospitals, Clinics, Others; Regional Analysis; Market Dynamics: SWOT Analysis; Supplier Landscape; 2024-2032
Nasopharyngeal Cancer Market Outlook
The nasopharyngeal cancer market size is expected to grow at a CAGR of 2.2% during the forecast period of 2024-2032, driven by increasing advances in immunotherapy and offering targeted therapies to patients to minimise cancer recurrence.
Nasopharyngeal Cancer Market Overview
Nasopharyngeal cancer is characterized by the presence of cancerous cells in the nasopharynx, which is present behind the nose and above the back of the throat. It is a rare cancer and accounts for less than one case in every 100,000 people per year in the United States. However, the prevalence is higher in South Asia, North Africa, the Middle East, and the Arctic region. In parts of China, there are about 25-30 cases per 100,000 males and 15-20 per 100,000 females, indicating that men are more likely to develop NPC than women.
A lump in the neck, blood in the saliva, bloody discharge from the nose, nasal congestion or hearing loss are some of the common symptoms of the disease. The risk gradually progresses as a person ages; however, it may affect children as well. In high-risk areas, such as China, the peak age of getting affected by the condition is typically between 45-59. While in the United States (low risk areas), cases are observed in young adulthood (15-24 years of age), followed by a decline until another peak at an older age (65-79).
Growth in FDA Approvals to Meet the Nasopharyngeal Cancer Market Demand
In October 2023, the FDA approved Loqtorzi , the combination of toripalimab, gemcitabine, and cisplatin as a first-tier treatment for adult patients with recurrent or locally advanced nasopharyngeal cancer. The approval was based on the results of phase 3 JUPITER-02 trials, wherein Loqtorzi combined with chemotherapy lowered the risk of disease progression or death by 48%, when compared to therapy alone. In May 2023, the FDA approved the pre-licensing inspection of Shanghai Junshi Biosciences’s manufacturing site in China. This shows that the global nasopharyngeal market share is expected to witness a dynamic shift, with increased production in the Asia Pacific region.
Technical Advancements in Cell Therapies
With a better understanding of biotechnology and gene therapy, researchers are also focused on developing effective therapeutic strategies for treatment. In July 2023, Biosyngen's cell therapy BRG01 received the fast-track designation by the FDA. BRG01 is an engineered T cell therapy that attacks the human herpesvirus EBBV, which has infected around 95% of the population and has been listed as a Group 1 carcinogen for nasopharyngeal cancer. The nasopharyngeal cancer market growth is fueled by the rising development in new treatment modalities and technologies, aimed at offering personalized treatment approaches to patients.
Application of Dual Immunotherapies to Treat Metastatic Nasopharyngeal Cancer
Conventionally NPC has been targeted with radiotherapy. While it cures around 90% of the patients with the early-stage disease, radiochemotherapy is used in those with advanced NPC. Over the years, immunotherapy has emerged as an active tool for clinical cancer management. Dual immunotherapies such as a combination of PD-1 and CTLA-4 are being investigated in treating NPC, along with other carcinomas. A combination of nivolumab and ipilimumab is currently under phase-2 trials. Therapeutic vaccinations that target EBNA1, LMP1 or LMP2 genes are also under consideration for treating NPC. With the help of such novel therapeutic approaches, scientists and healthcare companies aim to cater to the rising nasopharyngeal cancer market demand and offer effective patient outcomes.
Nasopharyngeal Cancer Market Segmentation
Market Breakup by Therapy
- Chemotherapy
- Immunotherapy
- Radiation therapy
- Others
Market Breakup by Diagnosis
- Biopsy
- MRI
- Others
Market Breakup by Stages
- Stage 1
- Stage 2
- Stage 3
- Stage 4
Market Breakup by End User
- Hospitals
- Clinics
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Nasopharyngeal Cancer Market Regional Analysis
Nasopharyngeal cancer is more prevalent in South Asia, therefore, the Asia Pacific region is projected to lead the nasopharyngeal cancer market share in the forecast period. While Japan is the leading market, other countries such India, South Korea and China are also rising as potential markets with increasing investments to build the healthcare infrastructure and upskill the medical staff efficiently.
The United States with a robust medical ecosystem along with research and development infrastructure holds significant portion of the nasopharyngeal cancer market value. The rising number of drug approvals and drug development is driving the market growth in the region. In addition, the presence of vital healthcare companies and stringent regulatory bodies such as FDA ensure the efficacy of therapeutic solutions being offered to patients. There is rising importance on building better diagnostic services that provide precise and prompt results of disease progression in patients.
Europe with countries like United Kingdom, France, Spain, and Italy is another leading market. With multiple academic as well as research institutions, the region leads in devising innovative solutions for the patients. Moreover, there is heavy emphasis on educating the population by reading early signs of nasopharyngeal cancer to facilitate prompt treatment and minimize the risk of mortality.
Nasopharyngeal Cancer Market: Competitor Landscape
In September 2023, Coherus BioSciences, Inc. acquired Surface Oncology, Inc., a clinical-stage immuno-oncology (I-O) company that develops immunotherapies targeting tumour microenvironment. With the acquisition, Coherus aims to expand the application of their recently approved late-stage, anti-PD-1 monoclonal antibody candidate for the potential treatment of advanced recurrent or metastatic nasopharyngeal carcinoma (NPC) – Toripalimab. The agreement also brings three other differentiated clinical assets into the market landscape. Such mergers and partnerships are anticipated to address the unmet needs of people suffering from fatal illnesses.
The key features of the nasopharyngeal cancer market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Biocon Limited
- Bristol Myers Squibb
- Cyclacel Pharmaceuticals
- F. Hoffman-La Roche Ltd.
- Merck & Co.
- Novartis AG
- Pfizer
- Sanofi
- Theravectys SA
- Eli Lilly and Company
- GlaxoSmithKline (GSK) PLC
- Celgene Corporation
- BioDiem Ltd
- Fresenius SE & Co. KGaA
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Therapy |
|
| Breakup by Diagnosis |
|
| Breakup by Stages |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Nasopharyngeal Cancer Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Nasopharyngeal Cancer Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Nasopharyngeal Cancer Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Nasopharyngeal Cancer Epidemiology Forecast (2017-2032)
5.3.1 Germany Nasopharyngeal Cancer Epidemiology Forecast (2017-2032)
5.3.2 France Nasopharyngeal Cancer Epidemiology Forecast (2017-2032)
5.3.3 Italy Nasopharyngeal Cancer Epidemiology Forecast (2017-2032)
5.3.4 Spain Nasopharyngeal Cancer Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Nasopharyngeal Cancer Epidemiology Forecast (2017-2032)
5.4 Japan Nasopharyngeal Cancer Epidemiology Forecast (2017-2032)
6 Nasopharyngeal Cancer Market Overview – 7MM
6.1 Nasopharyngeal Cancer Market Historical Value (2017-2023)
6.2 Nasopharyngeal Cancer Market Forecast Value (2024-2032)
7 Nasopharyngeal Cancer Market Landscape – 7MM
7.1 Nasopharyngeal Cancer Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Nasopharyngeal Cancer Product Landscape
7.2.1 Analysis by Products
7.2.2 Analysis by Indications
7.2.3 Analysis by Route of Administration
8 Nasopharyngeal Cancer Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Nasopharyngeal Cancer Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Nasopharyngeal Cancer Market Segmentation – 7MM
11.1 Nasopharyngeal Cancer Market by Therapy
11.1.1 Market Overview
11.1.2 Chemotherapy
11.1.3 Immunotherapy
11.1.4 Radiation therapy
11.1.5 Others
11.2 Nasopharyngeal Cancer Market by Diagnosis
11.2.1 Market Overview
11.2.2 Biopsy
11.2.3 MRI
11.2.4 Others
11.3 Nasopharyngeal Cancer Market by Stages
11.3.1 Market Overview
11.3.2 Stage 1
11.3.3 Stage 2
11.3.4 Stage 3
11.3.5 Stage 4
11.4 Nasopharyngeal Cancer Market by End User
11.4.1 Market Overview
11.4.2 Hospitals
11.4.3 Clinics
11.4.4 Others
11.5 Nasopharyngeal Cancer Market by Region
11.5.1 Market Overview
11.5.2 United States
11.5.3 EU-4 and the United Kingdom
11.5.3.1 Germany
11.5.3.2 France
11.5.3.3 Italy
11.5.3.4 Spain
11.5.3.5 United Kingdom
11.5.4 Japan
12 United States Nasopharyngeal Cancer Market
12.1 Nasopharyngeal Cancer Market Historical Value (2017-2023)
12.2 Nasopharyngeal Cancer Market Forecast Value (2024-2032)
12.3 Nasopharyngeal Cancer Market by Diagnosis
12.4 Nasopharyngeal Cancer Market by Therapy
13 EU-4 and United Kingdom Nasopharyngeal Cancer Market
13.1 Nasopharyngeal Cancer Market Historical Value (2017-2023)
13.2 Nasopharyngeal Cancer Market Forecast Value (2024-2032)
13.3 Germany Nasopharyngeal Cancer Market Overview
13.3.1 Nasopharyngeal Cancer Market by Diagnosis
13.3.2 Nasopharyngeal Cancer Market by Therapy
13.4 France Nasopharyngeal Cancer Market Overview
13.4.1 Nasopharyngeal Cancer Market by Diagnosis
13.4.2 Nasopharyngeal Cancer Market by Therapy
13.5 Italy Nasopharyngeal Cancer Market Overview
13.5.1 Nasopharyngeal Cancer Market by Diagnosis
13.5.2 Nasopharyngeal Cancer Market by Therapy
13.6 Spain Nasopharyngeal Cancer Market Overview
13.6.1 Nasopharyngeal Cancer Market by Diagnosis
13.6.2 Nasopharyngeal Cancer Market by Therapy
13.7 United Kingdom Nasopharyngeal Cancer Market Overview
13.7.1 Nasopharyngeal Cancer Market by Diagnosis
13.7.2 Nasopharyngeal Cancer Market by Therapy
14 Japan Nasopharyngeal Cancer Market
14.1 Nasopharyngeal Cancer Market Historical Value (2017-2023)
14.2 Nasopharyngeal Cancer Market Forecast Value (2024-2032)
14.2.1 Nasopharyngeal Cancer Market by Diagnosis
14.2.2 Nasopharyngeal Cancer Market by Therapy
15 Patent Analysis
15.1 Analysis by Type of Patent
15.2 Analysis by Publication year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
15.7 Analysis by Key Players
16 Grants Analysis
16.1 Analysis by year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Clinical Trials Analysis
17.1 Analysis by Trial Registration Year
17.2 Analysis by Trial Status
17.3 Analysis by Trial Phase
17.4 Analysis by Therapeutic Area
17.5 Analysis by Geography
18 Funding Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 Biocon Limited
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisition
20.1.5 Certifications
20.2 Bristol Myers Squibb
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisition
20.2.5 Certifications
20.3 Cyclacel Pharmaceuticals
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisition
20.3.5 Certifications
20.4 F. Hoffman-La Roche Ltd.
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisition
20.4.5 Certifications
20.5 Merck & Co.
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisition
20.5.5 Certifications
20.6 Novartis AG
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisition
20.6.5 Certifications
20.7 Pfizer
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisition
20.7.5 Certifications
20.8 Sanofi
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisition
20.8.5 Certifications
20.9 Theravectys SA
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisition
20.9.5 Certifications
20.10 Eli Lilly and Company
20.10.1 Financial Analysis
20.10.2 Product Portfolio
20.10.3 Demographic Reach and Achievements
20.10.4 Mergers and Acquisition
20.10.5 Certifications
20.11 GlaxoSmithKline (GSK) PLC
20.11.1 Financial Analysis
20.11.2 Product Portfolio
20.11.3 Demographic Reach and Achievements
20.11.4 Mergers and Acquisition
20.11.5 Certifications
20.12 Celgene Corporation
20.12.1 Financial Analysis
20.12.2 Product Portfolio
20.12.3 Demographic Reach and Achievements
20.12.4 Mergers and Acquisition
20.12.5 Certifications
20.13 BioDiem Ltd
20.13.1 Financial Analysis
20.13.2 Product Portfolio
20.13.3 Demographic Reach and Achievements
20.13.4 Mergers and Acquisition
20.13.5 Certifications
20.14 Fresenius SE & Co. KGaA
20.14.1 Financial Analysis
20.14.2 Product Portfolio
20.14.3 Demographic Reach and Achievements
20.14.4 Mergers and Acquisition
20.14.5 Certifications
21 Nasopharyngeal Cancer Market - Distribution Model (Additional Insight)
21.1 Overview
21.2 Potential Distributors
21.3 Key Parameters for Distribution Partner Assessment
22 Key Opinion Leaders (KOL) Insights (Additional Insight)
23 Company Competitiveness Analysis (Additional Insight)
23.1 Very Small Companies
23.2 Small Companies
23.3 Mid-Sized Companies
23.4 Large Companies
23.5 Very Large Companies
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
24.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 2.2% during the forecast period of 2024-2032, driven rising advances in immunotherapy and providing targeted therapies to patients to minimise tumour relapse.
The market demand is majorly driven by increasing incidence of cases owing to increased susceptibility genetic mutations. Technical advancements in the research and development for treatment along with increasing disposable investments also aid the market demand.
The current market trend includes rising number of FDA approvals and application of combination therapies to treat the disease. In October 2023, the FDA approved Loqtorzi, the combination of toripalimab, gemcitabine, and cisplatin as a primary therapeutic approach for adult patients with recurrent nasopharyngeal cancer.
Major therapies include chemotherapy, immunotherapy, and radiation therapy, among others.
Biopsy and MRI, among others are typically used as diagnostic methods.
Based on stages, the market is divided into stage 1, stage 2, stage 3, and stage 4.
Major end users include hospitals and clinics, among others.
The major regions of the market include the United States, Japan, EU-4 which is segmented into Germany, France, Italy, Spain, and the United Kingdom.
Key players involved in the market are Biocon Limited, Bristol Myers Squibb, Cyclacel Pharmaceuticals, F. Hoffman-La Roche Ltd., Merck & Co., Novartis AG, Pfizer, Sanofi, Theravectys SA, Eli Lilly and Company, GlaxoSmithKline (GSK) PLC., BioDiem Ltd, Fresenius SE & Co. KGaA, and Celgene Corporation.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER